Hiring, training, and supporting Peer Research Associates: Operationalizing community-based research principles within epidemiological studies by, with, and for women living with HIV.
Canada
Clinical Competence
/ legislation & jurisprudence
Cohort Studies
Community-Based Participatory Research
/ statistics & numerical data
Criminal Law
/ legislation & jurisprudence
Drug Overdose
/ rehabilitation
Epidemiologic Studies
Female
HIV Infections
Humans
Inservice Training
/ legislation & jurisprudence
Longitudinal Studies
Naloxone
/ therapeutic use
Narcotic Antagonists
/ therapeutic use
Peer Group
Personnel Selection
/ legislation & jurisprudence
Research
/ education
Research Design
Sex Factors
Social Marginalization
CHIWOS
Canada
Cohort studies
Community engagement
Community-based research
HIV
Harm reduction
Peers
Training
Women
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
18 07 2019
18 07 2019
Historique:
received:
30
01
2019
accepted:
29
05
2019
entrez:
20
7
2019
pubmed:
20
7
2019
medline:
17
6
2020
Statut:
epublish
Résumé
A community-based research (CBR) approach is critical to redressing the exclusion of women-particularly, traditionally marginalized women including those who use substances-from HIV research participation and benefit. However, few studies have articulated their process of involving and engaging peers, particularly within large-scale cohort studies of women living with HIV where gender, cultural and linguistic diversity, HIV stigma, substance use experience, and power inequities must be navigated. Through our work on the Canadian HIV Women's Sexual and Reproductive Health Cohort Study (CHIWOS), Canada's largest community-collaborative longitudinal cohort of women living with HIV (n = 1422), we developed a comprehensive, regionally tailored approach for hiring, training, and supporting women living with HIV as Peer Research Associates (PRAs). To reflect the diversity of women with HIV in Canada, we initially hired 37 PRAs from British Columbia, Ontario, and Quebec, prioritizing women historically under-represented in research, including women who use or have used illicit drugs, and women living with HIV of other social identities including Indigenous, racialized, LGBTQ2S, and sex work communities, noting important points of intersection between these groups. Building on PRAs' lived experience, research capacity was supported through a comprehensive, multi-phase, and evidence-based experiential training curriculum, with mentorship and support opportunities provided at various stages of the study. Challenges included the following: being responsive to PRAs' diversity; ensuring PRAs' health, well-being, safety, and confidentiality; supporting PRAs to navigate shifting roles in their community; and ensuring sufficient time and resources for the translation of materials between English and French. Opportunities included the following: mutual capacity building of PRAs and researchers; community-informed approaches to study the processes and challenges; enhanced recruitment of harder-to-reach populations; and stronger community partnerships facilitating advocacy and action on findings. Community-collaborative studies are key to increasing the relevance and impact potential of research. For women living with HIV to participate in and benefit from HIV research, studies must foster inclusive, flexible, safe, and reciprocal approaches to PRA engagement, employment, and training tailored to regional contexts and women's lives. Recommendations for best practice are offered.
Sections du résumé
BACKGROUND
A community-based research (CBR) approach is critical to redressing the exclusion of women-particularly, traditionally marginalized women including those who use substances-from HIV research participation and benefit. However, few studies have articulated their process of involving and engaging peers, particularly within large-scale cohort studies of women living with HIV where gender, cultural and linguistic diversity, HIV stigma, substance use experience, and power inequities must be navigated.
METHODS
Through our work on the Canadian HIV Women's Sexual and Reproductive Health Cohort Study (CHIWOS), Canada's largest community-collaborative longitudinal cohort of women living with HIV (n = 1422), we developed a comprehensive, regionally tailored approach for hiring, training, and supporting women living with HIV as Peer Research Associates (PRAs). To reflect the diversity of women with HIV in Canada, we initially hired 37 PRAs from British Columbia, Ontario, and Quebec, prioritizing women historically under-represented in research, including women who use or have used illicit drugs, and women living with HIV of other social identities including Indigenous, racialized, LGBTQ2S, and sex work communities, noting important points of intersection between these groups.
RESULTS
Building on PRAs' lived experience, research capacity was supported through a comprehensive, multi-phase, and evidence-based experiential training curriculum, with mentorship and support opportunities provided at various stages of the study. Challenges included the following: being responsive to PRAs' diversity; ensuring PRAs' health, well-being, safety, and confidentiality; supporting PRAs to navigate shifting roles in their community; and ensuring sufficient time and resources for the translation of materials between English and French. Opportunities included the following: mutual capacity building of PRAs and researchers; community-informed approaches to study the processes and challenges; enhanced recruitment of harder-to-reach populations; and stronger community partnerships facilitating advocacy and action on findings.
CONCLUSIONS
Community-collaborative studies are key to increasing the relevance and impact potential of research. For women living with HIV to participate in and benefit from HIV research, studies must foster inclusive, flexible, safe, and reciprocal approaches to PRA engagement, employment, and training tailored to regional contexts and women's lives. Recommendations for best practice are offered.
Identifiants
pubmed: 31319894
doi: 10.1186/s12954-019-0309-3
pii: 10.1186/s12954-019-0309-3
pmc: PMC6637632
doi:
Substances chimiques
Narcotic Antagonists
0
Naloxone
36B82AMQ7N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
47Subventions
Organisme : CIHR
ID : MOP-111041
Pays : Canada
Organisme : Canadian HIV Trials Network, Canadian Institutes of Health Research
ID : CTN 262
Pays : International
Organisme : Ontario HIV Treatment Network
ID : .
Pays : International
Organisme : Academic Health Science Centres (AHSC) Alternative Funding Plans (AFP) Innovation Fund
ID : .
Pays : International
Organisme : Doctoral Research Award, CIHR HIV/AIDS Research Initiative
ID : .
Pays : International
Organisme : Fonds de Recherche du Québec - Santé
ID : .
Pays : International
Organisme : Fonds de Recherche du Québec - Santé
ID : .
Pays : International
Organisme : Tier 2 Canada Research Chair in Global Perspectives on HIV and Sexual and Reproductive Health
ID : .
Pays : International
Investigateurs
Rahma Abdul-Noor
(R)
Aranka Anema
(A)
Jonathan Angel
(J)
Dada Mamvula Bakombo
(DM)
Fatimatou Barry
(F)
Greta Bauer
(G)
Kerrigan Beaver
(K)
Marc Boucher
(M)
Isabelle Boucoiran
(I)
Jason Brophy
(J)
Lori Brotto
(L)
Ann Burchell
(A)
Claudette Cardinal
(C)
Allison Carter
(A)
Lynne Cioppa
(L)
Tracey Conway
(T)
José Côté
(J)
Jasmine Cotnam
(J)
Cori d'Ambrumenil
(C)
Janice Dayle
(J)
Erin Ding
(E)
Danièle Dubuc
(D)
Janice Duddy
(J)
Mylène Fernet
(M)
Annette Fraleigh
(A)
Peggy Frank
(P)
Brenda Gagnier
(B)
Marilou Gagnon
(M)
Jacqueline Gahagan
(J)
Claudine Gasingirwa
(C)
Nada Gataric
(N)
Rebecca Gormley
(R)
Saara Greene
(S)
Danielle Groleau
(D)
Charlotte Guerlotté
(C)
Trevor Hart
(T)
Catherine Hankins
(C)
Emily Heer
(E)
Robert S Hogg
(RS)
Terry Howard
(T)
Shazia Islam
(S)
Joseph Jean-Gilles
(J)
Hermione Jefferis
(H)
Evin Jones
(E)
Charu Kaushic
(C)
Mina Kazemi
(M)
Mary Kestler
(M)
Maxime Kiboyogo
(M)
Marina Klein
(M)
Nadine Kronfli
(N)
Gladys Kwaramba
(G)
Gary Lacasse
(G)
Ashley Lacombe-Duncan
(A)
Melanie Lee
(M)
Rebecca Lee
(R)
Jenny Li
(J)
Viviane Lima
(V)
Elisa Lloyd-Smith
(E)
Carmen Logie
(C)
Evelyn Maan
(E)
Valérie Martel-Lafrenière
(V)
Carrie Martin
(C)
Renee Masching
(R)
Lyne Massie
(L)
Melissa Medjuck
(M)
Brigitte Ménard
(B)
Cari L Miller
(CL)
Judy Mitchell
(J)
Gerardo Mondragon
(G)
Deborah Money
(D)
Ken Monteith
(K)
Marvelous Muchenje
(M)
Florida Mukandamutsa
(F)
Mary Ndung'u
(M)
Valerie Nicholson
(V)
Kelly O'Brien
(K)
Nadia O'Brien
(N)
Gina Ogilvie
(G)
Susanna Ogunnaike-Cooke
(S)
Joanne Otis
(J)
Rebeccah Parry
(R)
Sophie Patterson
(S)
Angela Paul
(A)
Doris Peltier
(D)
Neora Pick
(N)
Alie Pierre
(A)
Jeff Powis
(J)
Karène Proulx-Boucher
(K)
Corinna Quan
(C)
Jesleen Rana
(J)
Eric Roth
(E)
Danielle Rouleau
(D)
Geneviève Rouleau
(G)
Sergio Rueda
(S)
Kate Salters
(K)
Margarite Sanchez
(M)
Roger Sandre
(R)
Jacquie Sas
(J)
Édénia Savoie
(É)
Paul Sereda
(P)
Stephanie Smith
(S)
Marcie Summers
(M)
Wangari Tharao
(W)
Christina Tom
(C)
Cécile Tremblay
(C)
Jason Trigg
(J)
Sylvie Trottier
(S)
Angela Underhill
(A)
Anne Wagner
(A)
Sharon Walmsley
(S)
Clara Wang
(C)
Kath Webster
(K)
Wendy Wobeser
(W)
Denise Wozniak
(D)
Mark Yudin
(M)
Wendy Zhang
(W)
Julia Zhu
(J)
Références
AIDS Care. 2007 Feb;19(2):195-202
pubmed: 17364398
J Antimicrob Chemother. 2007 Oct;60(4):724-32
pubmed: 17715125
AIDS Patient Care STDS. 2009 Sep;23(9):775-83
pubmed: 19663745
Expert Opin Drug Metab Toxicol. 2006 Apr;2(2):273-83
pubmed: 16866613
Harm Reduct J. 2014 Oct 13;11(1):26
pubmed: 25307356
Health Care Women Int. 2015;36(8):936-64
pubmed: 25256222
HIV Med. 2011 Jul;12(6):352-60
pubmed: 21059167
J Acquir Immune Defic Syndr. 2007 Sep;46 Suppl 1:S3-8
pubmed: 17713423
Drug Alcohol Depend. 2018 Oct 1;191:70-77
pubmed: 30086425
BMC Med Res Methodol. 2016 Aug 19;16(1):101
pubmed: 27543135
J Int AIDS Soc. 2013 Jan 11;16:17433
pubmed: 23336725
PLoS One. 2017 Sep 28;12(9):e0184708
pubmed: 28957412
Am J Med Sci. 2010 Feb;339(2):133-40
pubmed: 20087169
PLoS One. 2014 Mar 18;9(3):e92334
pubmed: 24642949
AIDS Care. 2006 Oct;18(7):731-8
pubmed: 16971282
Harm Reduct J. 2016 Oct 7;13(1):26
pubmed: 27717364
Am J Public Health. 2000 Jul;90(7):1138-40
pubmed: 10897195
AIDS Care. 2014 Feb;26(2):263-6
pubmed: 23724932
Lancet. 2010 Aug 14;376(9740):532-9
pubmed: 20638713
Int J Epidemiol. 2004 Jun;33(3):499-506
pubmed: 15155709
BMC Infect Dis. 2015 Jul 17;15:274
pubmed: 26183704
Prog Community Health Partnersh. 2015 Winter;9(4):561-9
pubmed: 26639382
Can J Public Health. 2007 Nov-Dec;98(6):465-9
pubmed: 19039884
Health Care Women Int. 2002 Dec;23(8):794-808
pubmed: 12487695
JAMA. 2016 Jul 12;316(2):171-81
pubmed: 27404185
Prog Community Health Partnersh. 2018;12(1):21-34
pubmed: 29606690
J Empir Res Hum Res Ethics. 2013 Apr;8(2):141-52
pubmed: 23651938
Soc Sci Med. 2008 Jun;66(11):2185-94
pubmed: 18455054
AIDS. 2005 Mar 4;19(4):357-70
pubmed: 15750389
Lancet. 2006 Aug 5;368(9534):531-6
pubmed: 16890841
Annu Rev Public Health. 1998;19:173-202
pubmed: 9611617
J Empir Res Hum Res Ethics. 2012 Oct;7(4):10-9
pubmed: 23086044
J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):226-236
pubmed: 29916960
AIDS Care. 2008 Jul;20(6):615-24
pubmed: 18576163